590 reports of this reaction
2.2% of all BREXPIPRAZOLE reports
#8 most reported adverse reaction
TARDIVE DYSKINESIA is the #8 most commonly reported adverse reaction for BREXPIPRAZOLE, manufactured by Otsuka America Pharmaceutical, Inc.. There are 590 FDA adverse event reports linking BREXPIPRAZOLE to TARDIVE DYSKINESIA. This represents approximately 2.2% of all 26,345 adverse event reports for this drug.
Patients taking BREXPIPRAZOLE who experience tardive dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TARDIVE DYSKINESIA is a less commonly reported adverse event for BREXPIPRAZOLE, but still significant enough to appear in the safety profile.
In addition to tardive dyskinesia, the following adverse reactions have been reported for BREXPIPRAZOLE:
The following drugs have also been linked to tardive dyskinesia in FDA adverse event reports:
TARDIVE DYSKINESIA has been reported as an adverse event in 590 FDA reports for BREXPIPRAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TARDIVE DYSKINESIA accounts for approximately 2.2% of all adverse event reports for BREXPIPRAZOLE, making it a notable side effect.
If you experience tardive dyskinesia while taking BREXPIPRAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.